French company Carmat is hoping that its artificial hearts will be available to patients by 2015 and that its human trials will come to end in 2014. The company will need to be given regulatory approval by the EU before the product can be launched on the European market.
Camat's artificial heart is intended to replace a human heart for up to five years, with French authorities giving the go-ahead for the first human tests of the device in September. The company has also been approved to trial the device in Belgium, Poland, Slovenia and Saudi Arabia. The artificial heart as it currently stands weighs 900g and is estimated to cost between €140,000 (£117,000) and €180,000 (£150,000).